ALSO NOTED: Orexigen IPO gins $84M; Spherix to concentrate on biotech work; and much more...

> An investigation by the Senate Finance Committee has concluded that drug makers are using their financial clout to improperly influence Continuing Medical Education programs. Report

> Orexigen raised $84 million in an IPO priced in the middle of its forecasted range. Release

> Spherix has signed a letter of intent to sell the stock of its subsidiary, InfoSpherix Incorporated, in order to concentrate its efforts on drug development work. A Phase III trial for Naturlose as a treatment for type 2 diabetes is scheduled to begin soon. Release

> A report from PricewaterhouseCoopers Health Sciences practice says that the life sciences sector acts as the second biggest driver of economic growth in Massachusetts. But with other states offering a wide variety of incentives, Massachusetts needs to do more to foster the industry's continued growth. Release

> Biodel says it will price its IPO of 5 million shares at $14 to $16 per share. Report

> Texas lawmakers resoundingly rejected the governor's initiative to require sixth-grade girls to get vaccinated with Gardasil to protect them from cervical cancer. Report

> SciClone Pharmaceuticals has acquired the exclusive rights in the United States and Canada to develop RP101, a clinical-stage cancer compound, from a subsidiary of Avantogen Oncology. Release

> Carrington Laboratories has raised $8 million to help fund development of its drug and vaccine delivery technologies. Release

And Finally... Kannapolis, NC is looking to sell $168 million in bonds to help finance the infrastructure for a new biotech hub. Report

Suggested Articles

Chi-Med has detailed plans to seek approval from the FDA later this year in part on the strength of data from Chinese phase 3 trial.

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.

The role gives one of the driving forces behind Bristol Myers Squibb’s $74 billion takeover of Celgene the chance to help build biotechs.